We have a team of innovative and successful developers who have deep and collective experience about drug discovery development and commercialization at leading biotechnology and pharmaceutical companies. Our team is able to access a broad network that can determine the optimum development pathway for each project.
CEO Mr. Ahn has worked for pharmaceutical industry for about 30 years and launched breakthrough medicines in a major pharmaceutical company as a head of B/D and accomplished successful projects with global partners on unexperienced field. He is a committee of Korea pharmaceutical industry group and has an expertise in regulatory affair and global business development. He has extensive contacts with local governments and leading institutes.
Taking responsibility for regulatory affair related License in/out coordinating Preclinical & Clinical trials, ensuring price and supporting Market access.
In charge of administration and managing organization, internal lawyers and advisory board as well as dealing with PR and financial management.
Members with significant expertise in business development from introduction of early stage projects to commercial operations of late stage projects.
Our Advisory Board is composed of experts in science, cancer therapy and clinical developments.
They evaluate and guide our team, potential opportunities and will continue to play a critical role in improving our team to be a global leading biopharmaceutical company.
Dr. Choi is a Director of global marketing in NEXEL CO., LTD and working as a patent consultant at Aequitas Technologies, LLC, California, US.
He was a scientific director of Capital Disability Research center, Annandale, VA and Research scientists of National Institute of Health, Bethesda MD, for over 6 years.
Dr. Lee is currently a professor of KHU-KIST (KHU-KIST Department of Converging Science and Technology) since 2016 and an evaluation committee of Korea Health Industry Development Institute.
He studied at Dept. of Chemistry, University of Iowa, USA(Postdoc).
Dr. Yun is currently a Research scientist of antibody and head officer in future strategy team of Scrips Korea Antibody Institute.
He majored in Biotechnology and worked on roles of Expert advisor of Project evaluation team (Korean Drug Development Fund).
Dr. Jin is an assistant professor in Department of Convergence Medicine in Uni. Of Ulsan college of medicine and a professor of Center of Asan Drug Discovery Support.
He plays a role of an evaluation committee of Korean Drug Development Fund and works in WMBio as a CEO.
Dr. Chung is currently a medicinal specialist in The Korean Association of Internal Medicine and at the same time a branch specialist at Digestive medicine of The Korean Association of Internal Medicine.
He graduated from Yonsei University College of Medicine.
Dr. Yang is currently a chairman of Obesity injection research in Korean Academy of Obesity and Aesthetic treatment.
He was an adjunct professor at School of Medicine Kyung Hee University and Catholic Kwandong University International ST. MARY'S Hospital.
He worked at Kyung Hee University Healthcare System as a clinical instructor.
Dr. Yeom is leading a cancer hospital ( named of Yeom Chang Hwan Cancer Center) as a director currently.
He graduated from Yonsei University College of Medicine in Korea and studied Lymphedema at Lymph Academy in Florida, US and Cancer prevention at Michael Cancer Center in Kentucky, US.
He also took a course in Cancer Treatment Center in Philadelphia, US.
Dr. Kwon is currently an associate professor of Molecular biology and Biochemistry in College of Pharmacy, Yonsei University since 2015.
She majored in Biochemistry and obtained Doctor’s degree in Basel University &Friedrich Miescher Institute for Biochemical Research in Switzerland.
He is the vice president ( Legal and Chief compliance officer) of Samsung Bioepis.
Formerly he worked for Kim & Chang, the premier Law firm in Korea and served as Chief of Business Development as well as a legal head officer in GSK KOREA.